title: Introducing a specialist drug kardex can significantly change prescribing practices for VTE in cancer patients.
authors.forename: N
authors.initials: N
authors.lastname: Coleman
authors.forename: R
authors.initials: R
authors.lastname: Young
authors.forename: M
authors.initials: M
authors.lastname: Greally
authors.forename: L
authors.initials: L
authors.lastname: O'Riordan
authors.forename: O
authors.initials: O
authors.lastname: Breathnach
authors.forename: L
authors.initials: L
authors.lastname: Grogan
mesh_terms: D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008485:Medical Audit / Q000706:statistics & numerical data*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D054556:Venous Thromboembolism / Q000517:prevention & control*